Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Web based Dating Application - 2Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- 36 Methods for further developing Rest Quality
- 4Russian authorities threaten WhatsApp with total ban
- 5California is completely free of drought for the first time in 25 years
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- The Development of Shipping: Controlling Towards a More Associated Future
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- When is MLK Day? Plus, the dates of when other federal holidays land in 2026.
- Israel strikes south Lebanon after first direct talks in decades
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Viable Correspondence: Building Solid Connections
